1H-Purine-2,6-dione, 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dihydro-3,7-dimethyl-

CT-2584 (166981-13-1; free base) is a cytotoxic agent that alters phospholipid biosynthesis via inhibition of CTP:choline-phosphate cytidylyltransferase causing an increase in phosphatidylinositol with decreasing levels of phosphatidylcholine.1The altered phospholipid metabolism caused by CT-2584 results in a loss of lamellar structure and membrane integrity (especially in mitochondria and endoplasmic reticulum). CT-2584 was active against a wide range of tumor cell lines including multi-drug resistant lines.2

CT-2584 is a chemotherapeutic compound that reduces the expression of NKEF-B in several tumor cell types and kills tumor cells by inducing the production of ROS in mitochondria, commonly used in cancer research[1].

[1] R E FINNEY. Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines.[J]. Cancer research, 2000, 60 18: 5204-5213.
[2] S L CHEESEMAN. Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours[J]. British Journal of Cancer, 2000, 83 12: 1599-1606. DOI:10.1054/bjoc.2000.1503